LSL PHARMA GROUP PROVIDES UPDATE ON STERI-MED PHARMA MANUFACTURING OPERATIONS AND GRANTS COMPENSATION STOCK OPTIONS

BOUCHERVILLE, QC, July 6, 2026 /CNW/ - **LSL PHARMA GROUP INC.** (TSXV: LSL) (The "**Corporation**" or "**LSL Pharma**"), a Canadian integrated pharmaceutical company, is pleased to provide an update regarding the remediation plan initiated by Steri-Med Pharma Inc. ("**Steri-Med**"), as previously announced in the Corporation's news release dated April 30, 2026.

Steri-Med Manufacturing Operations

- **Operational Status.** Following Health Canada's biennial inspection, completed in late 2025, Steri-Med temporarily paused its sterile filling operations during the first quarter of 2026 to prepare and submit the remediation plan requested by Health Canada. After Health Canada accepted the remediation plan, production resumed in early April 2026, and manufacturing activities have continued without interruption since then.

- **Remediation Plan Progress.** As at the end of June 2026, execution of the remediation plan had reached a completion rate of 72%. The Corporation expects to complete the substantial majority of the planned initiatives by the beginning of the fourth quarter of 2026, in accordance with the agreed implementation schedule.

- **Compliance and Growth Benefits.** Management believes these initiatives will further strengthen Steri-Med's quality systems, regulatory compliance and manufacturing platform. These enhancements are also expected to reinforce the Company's position as a trusted North American manufacturer of sterile ophthalmic products that meet the rigorous standards of both Health Canada and the U.S. FDA.

Grant of Compensation Stock Options

LSL Pharma announced today that it has granted an aggregate of 1,175,000 stock options ("**Options**") to certain executives and employees, as part of their compensation. The Options have an exercise price of CAD $0.315 per share and are exercisable for a period of ten (10) years from the date of grant. Options granted to executives and employees vest over three (3) years. The Options were granted in accordance with the Corporation's Stock Option Plan.

All of the Options (and any Common Shares issuable upon exercise or settlement thereof) will be subject to a four-month hold period pursuant to the policies of the TSX Venture Exchange and applicable securities law.

About LSL Pharma Group Inc.

LSL Pharma Group Inc. is a Canadian integrated pharmaceutical company specializing in the development, manufacturing and commercialization of high-quality sterile ophthalmic pharmaceutical products, as well as pharmaceutical, cosmetic and natural health products in solid, semi-solid and liquid dosage forms. Leveraging its technical expertise, certified facilities, and experienced team, LSL Pharma delivers high-quality solutions that meet the highest industry standards. The wholly-owned subsidiaries of LSL Pharma include Steri-Med Pharma Inc., LSL Laboratory Inc., Virage Santé Inc., Dermolab Pharma Ltd., Du-Var Laboratory Inc. and LSL MedPlus Inc. (formerly Juno OTC Inc.) For more information, please visit our website at at www.groupelslpharma.com.

Cautionary Note Regarding Forward-Looking Statements

This press release may contain forward-looking statements as defined under applicable Canadian securities legislation. Forward looking statements include estimates and statements that describe the Company's future plans, objectives or goals, including words to the effect that the Company or management expects a stated condition, belief, estimate or opinion, or result to occur. Forward-looking statements may be identified by the use of forward-looking terminology such as "may", "will", "expect", "intend", "estimate", "believe", "aim", "plan" "continue" or similar expressions. Forward-looking statements are based on a number of assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's ability to control or predict, that could cause actual results or performance to differ materially from those expressed or implied in such forward-looking statements. These risks and uncertainties include, but are not limited to, potential changes in market conditions.

Readers are cautioned not to place undue reliance on forward-looking statements. No assurance can be given that any of the events referred to in the forward-looking statements will transpire, and if any of them do, the actual results, performance or achievements of the Corporation may differ materially from those expressed or implied by the forward-looking statements. All forward-looking statements contained in this press release speak only as of the date of this press release. The Corporation does not undertake to update these forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

For more information, please visit our website at **www.groupelslpharma.com.**

SOURCE Groupe LSL PHARMA INC.

View original content to download multimedia: http://www.newswire.ca/en/releases/archive/July2026/06/c7624.html

%SEDAR: 00030902E

For further information: François Roberge, President and Chief Executive Officer, (514) 664-7700, E-mail: Investors@groupelslpharma.com

CO: Groupe LSL PHARMA INC.

CNW 07:00e 06-JUL-26